Yet another therapy with FDA accelerated approval suffers a setback; Sage’s tough year continues; Sanofi drops $326 million ...

Novo expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the ...

On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 ...

In announcing the results, Novo Nordisk said Rybelsus, an oral glucagon-like peptide-1 (GLP-1) receptor agonist already ...

When you're taking GLP-1 medications for weight loss, it's easy for nutrition to get overlooked because while semaglutide ...

Bernstein said Novo Nordisk (NVO) study results that showed certain Rybelsus users had a 14% risk reduction for major ...

A late-stage study shows that Novo Nordisk's oral semaglutide, Rybelsus, cuts the risk of MACE by 14% in T2D patients ...

If you’ve listened to any weight-loss podcasts or watched the news in the past year, you’ve probably heard of the new drugs: ...

The global Oral proteins and peptides market is projected to reach USD 7.38 billion in 2024 will increase to USD 20.36 billion by 2029, with ...

The American Heart Association and the American Stroke Association issued guidelines Monday that also look at the effects of testosterone and estrogen on the body. Meanwhile, Eli Lilly sues three ...

In Novo Nordisk’s randomized clinical trial, semaglutide reduced the risk for major adverse cardiovascular events by 14% ...